Supercharged immune cells take on Hard-to-Treat cancers

NCT ID NCT06478251

Recruiting now Disease control Sponsor: TingBo Liang Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new type of cell therapy for people with advanced solid tumors that have specific KRAS mutations (G12V or G12D) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recognize and attack cancer cells carrying these mutations. The study is small (9 participants) and focuses on safety and dosing, while also looking for signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TCR-T cells targeting KRAS G12V or G12D mutations
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific KRAS mutations and no standard therapies left.
What could go wrong: This is a very early, small Phase 1 trial with only 9 participants, so it is primarily testing safety. The treatment may not shrink tumors or work for everyone, and there are risks from the cell therapy and chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUMOR, SOLID

Contacts and locations

Locations

The First Affiliated Hospital of Zhejiang University school of Medicine
RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.